Taken together, these data demonstrated that PDHX Lys 488 acetylation is an important determinant of liver cancer proliferation, and that DCA treatment specifically target the growth of glycolysis-dependent tumors through enhancing PDC activity. The gene discussed is PDHX; the disease is liver cancer.